Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 77.3%

Neg 0% Neu 77.3% Pos 0%

Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $30 price target.